These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 33626359)
1. TET2 is a component of the estrogen receptor complex and controls 5mC to 5hmC conversion at estrogen receptor cis-regulatory regions. Broome R; Chernukhin I; Jamieson S; Kishore K; Papachristou EK; Mao SQ; Tejedo CG; Mahtey A; Theodorou V; Groen AJ; D'Santos C; Balasubramanian S; Farcas AM; Siersbæk R; Carroll JS Cell Rep; 2021 Feb; 34(8):108776. PubMed ID: 33626359 [TBL] [Abstract][Full Text] [Related]
2. Regulation of TET2 gene expression and 5mC oxidation in breast cancer cells by estrogen signaling. Zhu X; Xiong L; Lyu R; Shen Y; Liu L; Li S; Argueta C; Tan L Biochem Biophys Res Commun; 2022 Jan; 589():240-246. PubMed ID: 34929447 [TBL] [Abstract][Full Text] [Related]
3. TET2 regulates extranodal NK/T cell lymphoma progression through regulation of DNA methylation. Xiang C; Gao L; Tao Q; Chen Z; Zhao S; Liu W Hematol Oncol; 2024 Jul; 42(4):e3295. PubMed ID: 38979860 [TBL] [Abstract][Full Text] [Related]
4. Genome-wide characterization of dynamic DNA 5-hydroxymethylcytosine and TET2-related DNA demethylation during breast tumorigenesis. Wu SL; Yang L; Huang C; Li Q; Ma C; Yuan F; Zhou Y; Wang X; Tong WM; Niu Y; Jin F Clin Epigenetics; 2024 Sep; 16(1):125. PubMed ID: 39261937 [TBL] [Abstract][Full Text] [Related]
5. TET2 coactivates gene expression through demethylation of enhancers. Wang L; Ozark PA; Smith ER; Zhao Z; Marshall SA; Rendleman EJ; Piunti A; Ryan C; Whelan AL; Helmin KA; Morgan MA; Zou L; Singer BD; Shilatifard A Sci Adv; 2018 Nov; 4(11):eaau6986. PubMed ID: 30417100 [TBL] [Abstract][Full Text] [Related]
6. Values of 5mC, 5hmC, and TET2 for identifying the presence and progression of breast precancerous lesion. Zhang Z; Jin Y; Zhang W; Chu C; Zhang K; Gao X; Zhou J; Zou L; Tang F; Wang H; Zou Q J Clin Lab Anal; 2020 May; 34(5):e23162. PubMed ID: 31867779 [TBL] [Abstract][Full Text] [Related]
7. Distinct and overlapping control of 5-methylcytosine and 5-hydroxymethylcytosine by the TET proteins in human cancer cells. Putiri EL; Tiedemann RL; Thompson JJ; Liu C; Ho T; Choi JH; Robertson KD Genome Biol; 2014 Jun; 15(6):R81. PubMed ID: 24958354 [TBL] [Abstract][Full Text] [Related]
8. Association of high 5-hydroxymethylcytosine levels with Ten Eleven Translocation 2 overexpression and inflammation in Sjögren's syndrome patients. Lagos C; Carvajal P; Castro I; Jara D; González S; Aguilera S; Barrera MJ; Quest AFG; Bahamondes V; Molina C; Urzúa U; Hermoso MA; Leyton C; González MJ Clin Immunol; 2018 Nov; 196():85-96. PubMed ID: 29894742 [TBL] [Abstract][Full Text] [Related]
10. High estrogen during ovarian stimulation induced loss of maternal imprinted methylation that is essential for placental development via overexpression of TET2 in mouse oocytes. Lu X; Mao J; Qian C; Lei H; Mu F; Sun H; Yan S; Fang Z; Lu J; Xu Q; Dong J; Su D; Wang J; Jin N; Chen S; Wang X Cell Commun Signal; 2024 Feb; 22(1):135. PubMed ID: 38374066 [TBL] [Abstract][Full Text] [Related]
12. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL. Poole CJ; Lodh A; Choi JH; van Riggelen J Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538 [TBL] [Abstract][Full Text] [Related]
13. Flanking sequences influence the activity of TET1 and TET2 methylcytosine dioxygenases and affect genomic 5hmC patterns. Adam S; Bräcker J; Klingel V; Osteresch B; Radde NE; Brockmeyer J; Bashtrykov P; Jeltsch A Commun Biol; 2022 Jan; 5(1):92. PubMed ID: 35075236 [TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma. Gong F; Guo Y; Niu Y; Jin J; Zhang X; Shi X; Zhang L; Li R; Chen L; Ma RZ Oncotarget; 2017 Jan; 8(1):315-328. PubMed ID: 27852070 [TBL] [Abstract][Full Text] [Related]
15. Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications. Lopez-Bertoni H; Johnson A; Rui Y; Lal B; Sall S; Malloy M; Coulter JB; Lugo-Fagundo M; Shudir S; Khela H; Caputo C; Green JJ; Laterra J Signal Transduct Target Ther; 2022 Feb; 7(1):37. PubMed ID: 35136034 [TBL] [Abstract][Full Text] [Related]
16. Tumour suppressor TET2 safeguards enhancers from aberrant DNA methylation and epigenetic reprogramming in ERα-positive breast cancer cells. Lyu R; Zhu X; Shen Y; Xiong L; Liu L; Liu H; Wu F; Argueta C; Tan L Epigenetics; 2022 Oct; 17(10):1180-1194. PubMed ID: 34689714 [TBL] [Abstract][Full Text] [Related]
17. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Theodorou V; Stark R; Menon S; Carroll JS Genome Res; 2013 Jan; 23(1):12-22. PubMed ID: 23172872 [TBL] [Abstract][Full Text] [Related]
18. Ten-eleven translocation 2 modulates allergic inflammation by 5-hydroxymethylcytosine remodeling of immunologic pathways. Meng C; Gu L; Li Y; Li R; Cao Y; Li Z; Allen EG; Zhu D; Jin P Hum Mol Genet; 2021 Oct; 30(21):1985-1995. PubMed ID: 34165552 [TBL] [Abstract][Full Text] [Related]
19. PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent. Song C; Wang L; Wu X; Wang K; Xie D; Xiao Q; Li S; Jiang K; Liao L; Yates JR; Lee JD; Yang Q Cancer Res; 2018 May; 78(10):2475-2489. PubMed ID: 29735542 [TBL] [Abstract][Full Text] [Related]
20. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function. Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]